Oct 18 (Reuters) - The federal trial judge overseeing a four-year-old multidistrict litigation over Merck’s Zostavax shingles vaccine decided in March 2022 that it was time for plaintiffs to put up or ...
After a drawn-out litigation process, Merck & Co. seems to have finally washed its hands of more than a thousand lawsuits tied to its shingles vaccine Zostavax. Late last week, the U.S. Court of ...
Merck & Co Inc (NYSE:MRK) has reportedly secured a significant legal victory as the 3rd U.S. Circuit Court of Appeals upheld the dismissal of nearly 1,200 lawsuits concerning its Zostavax shingles ...
GSK’s (GSK) shingles vaccine Shingrix is associated with a lower risk of major cardiovascular events such as stroke compared with Zostavax, a rival shot marketed by Merck (MRK), according to a new ...
The Merck vaccine is a regimen designed to prevent the onset of shingles, which is caused by the reemergence of dormant chicken pox virus.The U.S. Food and Drug Administration (FDA) has extended the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results